Abstract The determination of synergistic effects of antimicrobial drug combinations can lead to improved therapeutic options in the antibiotic treatment of cystic fibrosis patients who are chronically infected with multiresistant Pseudomonas aeruginosa isolates. The aim of this study was to evaluate the performance of the E test versus the standard agar dilution checkerboard susceptibility test in the assessment of synergy and, in addition, to determine the activity of two antimicrobial combinations against 163 multiresistant P. aeruginosa isolates from cystic fibrosis patients. The agreement between the checkerboard method and the E test was excellent (>90%) for nonmucoid as well as mucoid isolates from cystic fibrosis patients. The rate of synergy was higher for the antibiotic combination of ceftazidime and tobramycin (28.8% of the cystic fibrosis strains) than for the combination of meropenem and tobramycin (19.0%). However, the probability of synergy for the second antibiotic combination increased significantly when the synergy of the first antibiotic combination had already been demonstrated (Fischer's exact test, p=0.049). The results show that the E test is a valuable and practical method for routine microbiological diagnostics and can aid in the selection of improved antibiotic options in the treatment of cystic fibrosis patients chronically infected with P. aeruginosa.
Introduction
Pseudomonas aeruginosa has emerged as a major opportunistic pathogen and a significant source of life-threatening nosocomial infections. It is also the most dominant bacterial pathogen that can be recovered from the chronically infected lung of cystic fibrosis (CF) patients [1] [2] [3] [4] . Antimicrobial therapy has made an important contribution to increase the life expectancy of CF patients and is one of the cornerstones of the treatment of the disease [5, 6] . Due to the frequent requirement of antibiotic therapy for treating pulmonary exacerbation and to the slow progression of lung disease, multiresistant P. aeruginosa isolates are increasingly recovered [7] . Thus, antibiotic combinations that exhibit synergistic effects represent a valuable addition to standard treatment regimens and may overcome treatment failures [8] . To increase bactericidal activity, a combination of an aminoglycoside with a β-lactam antibiotic is generally used. This antimicrobial combination typically exhibits synergistic activity in vitro [9, 10] and increased efficacy in the treatment of CF patients [11, 12] . Synergism with drug combinations appears to be maintained within achievable therapeutic ranges, even at very high MICs [13] [14] [15] [16] . However, empirically chosen antibiotic combinations may not act synergistically against all multiresistant P. aeruginosa isolates [17, 18] , and, due to the unpredictable response of P. aeruginosa, assessment of the activity of antimicrobial combinations is necessary prior to starting therapy.
In vitro synergism between two antibiotics is usually determined by the checkerboard titration technique or by time-kill methods. However, as the performance of these methods is very time-and material-consuming, neither is used in routine microbiological diagnostics. Recently, the E test has been successfully used to assess the activity of antimicrobial agents against various bacterial pathogens, including Pseudomonas species [19] [20] [21] [22] , and it has been suggested that the E test may provide an alternative method for the evaluation of synergy [23] [24] [25] . The present study was designed to compare the reliability and reproducibility of the E test versus the checkerboard agar dilution method for assessing the activity of antimicrobial combinations against P. aeruginosa CF isolates known to exhibit phenotypes that adversely affect the performance and interpretation of standard antimicrobial susceptibility testing. A secondary objective was to define the degree of synergism of either ceftazidime or meropenem combined with tobramycin in a total of 163 ceftazidime-and meropenem-resistant P. aeruginosa isolates recovered from CF patients at two German CF centres (Munich/Hanover).
Materials and methods

Bacterial strains
One hundred sixty-three multiresistant CF isolates of P. aeruginosa were included in this study. Seventy isolates were recovered from 24 patients who attended the CF outpatient clinic in Hanover, Germany, within a 5-month period in 2002 [26] . A total of 93 clinical isolates of P. aeruginosa were recovered from 58 patients at the CF outpatient clinic in Munich, Germany, during the period 1998-2004. Multiple isolates from the same patient were included if they exhibited different phenotypes (e.g., mucoid versus nonmucoid).
The bacterial strains were identified as P. aeruginosa on the basis of a positive oxidase reaction, positive catalase, growth at 42°C, and pigment production. When necessary, strains were further evaluated using the API 20 NE system (bioMérieux, Marcy-l'Etoile, France). The strains were stored at −70°C. After thawing, they were subcultured twice onto Columbia blood agar (Becton Dickinson, Heidelberg, Germany) and checked for purity before susceptibility testing was performed.
P. aeruginosa ATCC 27853 was included as a quality control strain for all MIC determinations.
Determination of MICs
The MICs of tobramycin, ceftazidime, and meropenem were determined for the 163 multiresistant P. aeruginosa isolates by both the agar dilution method and the E test. Susceptibility testing was performed on 18-24 h subcultures of the clinical strains. A single inoculum adjusted to a McFarland standard of 0.5 in 0.9% NaCl (densimat; bioMérieux) was used. Standard agar dilution was performed according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS, now CLSI) [27] . Cation-adjusted Mueller-Hinton agar plates containing a serial twofold dilution of the antimicrobial agents were prepared in-house. The plates were stored at 4°C and used within 5 days. Inoculation was performed with an AM80 automatic inoculator (Dynatech, Zug, Switzerland), and the MIC results were recorded after an incubation time of 18-24 h at 36°C. NCCLS breakpoints were used for the assessment of interpretive category results [27] . The checkerboard method was performed the same way, using two combinations of antibiotics: ceftazidime (Glaxo-Wellcome, Hamburg, Germany) with tobramycin (Infectopharm, Heppenheim, Germany), and meropenem (Astra Zeneca, Wedel, Germany) with tobramycin. The antibiotic concentrations ranged from 0.25 to 32 μg/ml for ceftazidime, from 0.125 to 16 μg/ml for meropenem, and from 0.25 to 32 μg/ml for tobramycin.
For the E test, Mueller-Hinton agar plates (Becton Dickinson, Cockeysville, MD, USA) were inoculated with swabs saturated with suspensions of the test organism equivalent to a 0.5 McFarland standard for nonmucoid strains and equivalent to a 1.0 McFarland for mucoid strains. For the evaluation of the MICs of single antimicrobial agents, the E test strips (AB Biodisk, Solna, Sweden) were brought to room temperature prior to use and placed onto an agar plate. The E test results with one-half increment were rounded up to the next highest twofold dilution before comparison with the results of the agar dilution method. The antibiotic concentration range of the E test was 0.016-256 μg/ml for ceftazidime, 0.002-32 μg/ml for meropenem, and 0.016-256 μg/ml for tobramycin. The results were read after 18-24 h of incubation at 36°C. The MIC was interpreted as the value at which the inhibition zone intersected the scale on the E test strip. For testing of drug combinations, an antibiotic strip was placed onto an agar plate at room temperature as described previously [24] and removed after 1 h. Afterwards, a second antibiotic strip was placed on top of the gradient of the first agent. To evaluate the effect of an antibiotic combination, the fractional inhibitory concentration (FIC) index was calculated as follows:
FIC index=(FIC of drug A)+(FIC of drug B), where FIC of drug A=(MIC of drug A in combination)÷(MIC of drug A alone), and FIC of drug B=(MIC of drug B in combination)÷(MIC of drug B alone). Synergism was defined as an FIC index of ≤0.5, additivity as an FIC index of >0.5≤1, indifference as an FIC index of >1≤2, and antagonism as an FIC index of >2.
Results
Characteristics of the strains
The P. aeruginosa strains tested in this study were multiresistant isolates recovered from the respiratory tract of patients who attended the CF outpatient clinic in Hanover or Munich. Seventy strains were isolated in Hanover and 93 in Munich. The interpretive category results of the strains were determined by both the reference agar dilution method and the E test and are listed in Table 1 . Susceptibility testing by the agar dilution method was performed in Hanover and in Munich (according to the origin of the isolates), whereas susceptibility testing by the E test was performed in Hanover for all 163 P. aeruginosa strains. None of the 163 strains were susceptible to meropenem or ceftazidime by either susceptibility test method (inclusion criteria of this study), whereas more than 60% of the isolates were tobramycin susceptible.
Reproducibility and interlaboratory variability
The reproducibility of the MIC results was determined for both the E test and the agar dilution susceptibility test method. The MICs of ceftazidime, meropenem, and tobramycin for eight P. aeruginosa isolates were determined at four different points in time by both methods. The MICs of the three antibiotic agents for all strains were within 1 log 2 dilution as determined by both susceptibility testing methods, indicating excellent reproducibility. The interlaboratory variability of the E test MIC results was also determined. The MICs of all three antimicrobial agents for the eight P. aeruginosa isolates as determined by the E test in Munich were equivalent (within 1 log 2 dilution) to those obtained in Hanover.
Correlation The second major aim of this study was to determine the in vitro efficacy of the antimicrobial combinations ceftazidime-tobramycin and meropenem-tobramycin against the 163 multiresistant clinical isolates of P. aeruginosa from CF patients. Overall, the antibiotic combination of ceftazidime and tobramycin was more effective than the antibiotic combination of meropenem and tobramycin (Table 2) . More synergistic effects and fewer antagonistic effects were observed for the antibiotic combination of ceftazidime-tobramycin. Whereas overall additivity was the most dominant effect observed with the antibiotic combination of ceftazidime-tobramycin by both test methods, indifference was the most dominant effect as determined by the checkerboard agar dilution method and additivity the most dominant effect as determined by the E test for the antibiotic combination of meropenem-tobramycin. A separate analysis of synergy testing among mucoid and nonmucoid strains revealed comparable results for both phenotypes. We further determined whether the FIC indices of the two antibiotic combinations were linked. For example, synergism of both antibiotic combinations as determined by the E test was observed in 13 of 163 multiresistant P. aeruginosa isolates (Table 3) , while the expected FIC index would have been 8.94. Fisher's exact test revealed a significant dependency (p=0.049) of the FIC indices on the two antibiotic combinations.
Discussion
In CF patients, multiresistant P. aeruginosa strains are continuously emerging due to prolonged and frequent administration of antimicrobial therapy to manage pulmonary exacerbations. In order for patients to benefit further from antimicrobial therapy, a combination of two antipseudomonal antibiotics is usually administered and has been shown to be superior to monotherapy in P. aeruginosa infections [11, 12] . Since susceptibility testing at microbiological laboratories is traditionally performed for single antibiotics, antimicrobial combinations are usually chosen empirically. However, the response of P. aeruginosa to various antimicrobial combinations has been shown to be unpredictable, and thus an empirically chosen antimicrobial combination can be potentially counterproductive. Hence, to increase the therapeutic options available to the clinician, a simple and reproducible technique to detect in vitro synergy would be desirable.
In this study, we systematically analysed the performance of the E test for synergy testing in comparison to the checkerboard agar dilution method. A total of 163 highly resistant clinical CF isolates of P. aeruginosa-nonmucoid and mucoid strains-were included in this study. CF strains were anticipated to be problematic in the performance of susceptibility testing [19] , and we therefore aimed to evaluate whether the results of two methods remained comparable. We chose ceftazidime and meropenem in combination with tobramycin as the two antibiotic combinations to be evaluated in this study, as both combinations are commonly used in the clinical setting and have been previously described to act synergistically [16, 28] . In this study, the MICs of single antibiotics as determined by the E test correlated well with those obtained by the agar dilution method, and no serious errors were recorded. This is in accordance with several previous studies that have reported good correlation of the MIC results of the E test with those of the agar dilution susceptibility testing for various antimicrobial agents [19, [21] [22] [23] 29] . Moreover, the reproducibility of MIC results as determined by the E test was excellent, and no serious discrepancies were recorded, even when MIC values obtained at different laboratories were compared. Although several studies reported the good correlation of the E test Sensitivity  13  22  7  5  47  Additivity  17  34  13  12  76  Indifference  1  12  7  8  28  Antagonism  0  5  2  5  12  Total  31  73  29  30  163 MIC results with standard agar dilution susceptibility testing of single antibiotics, there are very few data on the performance of the E test in the detection of synergy [23] [24] [25] . In this study, antimicrobial combinations were tested by superimposing the E test strips on the same agar plate. A comparison of the results with those obtained by checkerboard agar dilution revealed that the overall agreement between the two methods for the synergism exhibited by the 163 clinical P. aeruginosa CF isolates was >90%. Whereas more synergism or antagonism was observed using the E test (Table 2) , the checkerboard agar dilution revealed additivity or indifference more frequently.
The second major aim of this study was to evaluate the synergistic activity of antimicrobial combinations on 163 clinical isolates of multiresistant P. aeruginosa from CF patients. The antibiotic combination of ceftazidime-tobramycin was slightly more effective than the combination of meropenem-tobramycin (t test p=0.035). Overall, 75.5 and 63.8% of the strains were affected by synergism or additivity by the respective antimicrobial combination, which is in good agreement with the results of a previous study on the antimicrobial susceptibility of multiresistant P. aeruginosa strains [30] . Not only was the rate of synergism higher, but the rate of antagonism also was lower for the combination of ceftazidime-tobramycin as compared to meropenem-tobramycin. This had been demonstrated previously in a study that evaluated the synergistic activity of ceftazidime and a carbapenem in combination with tobramycin against P. aeruginosa CF isolates using an automated broth microdilution checkerboard test system [31] .
Another finding of our study was that the results of synergy testing as determined for the two antibiotic combinations were not independent. If, for one particular P. aeruginosa strain, synergy had been demonstrated for one antibiotic combination, there was a significantly increased rate of synergism observed with the second antibiotic combination (p=0.049, Fischer's exact test). The assessment of the in vitro synergy of antimicrobial combinations will provide more options for successful antibiotic therapy in the clinical setting. The results of this study demonstrate that the E test is a rapid, reproducible, easy-to-perform, and flexible method for the determination of synergistic activity that could significantly contribute to the improvement of therapeutic options in the treatment of chronic P. aeruginosa infections. Future clinical studies will have to elucidate whether in vitro synergy testing is useful in the clinical setting and whether the results of synergy testing influence the clinical outcome in CF patients colonised with multiresistant P. aeruginosa strains.
